ACTA1 and Hepatic fibrosis: Further, the data also indicate that a 50% reduction in αSMA is likely to translate into a clinically meaningful reduction in liver fibrosis (i.e., one stage reduction in fibrosis) strengthening the notion that αSMA is an early biomarker of liver fibrosis.